Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$5.76 -8.0%	$8.21	$5.50 ▼ $11.99	$122.82M	N/A	60,930 shs	87,198 shs
CGEM Cullinan Therapeutics	$7.53 -3.1%	$8.02	$6.85 ▼ $21.01	$458.54M	-0.08	497,182 shs	221,414 shs
MBX MBX Biosciences	$11.75 -3.6%	$11.80	$4.81 ▼ $27.50	$392.73M	N/A	264,355 shs	273,419 shs
RZLT Rezolute	$5.39 -2.7%	$4.37	$2.22 ▼ $6.19	$473.78M	1.03	669,654 shs	664,138 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	-7.99%	-6.19%	-23.10%	-28.00%	+575,999,900.00%
CGEM Cullinan Therapeutics	-3.09%	-2.21%	-7.72%	-4.56%	-59.32%
MBX MBX Biosciences	-3.61%	-9.89%	+14.30%	+54.20%	+1,174,999,900.00%
RZLT Rezolute	-2.71%	+2.47%	+32.43%	+96.00%	+16.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	2.5981 of 5 stars	3.5	0.0	2.7	3.3	0.0
CGEM Cullinan Therapeutics	1.7555 of 5 stars	3.5	0.0	2.2	1.7	0.6
MBX MBX Biosciences	2.3633 of 5 stars	3.5	0.0	2.5	1.7	0.6
RZLT Rezolute	2.4397 of 5 stars	3.6	1.0	2.0	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	255.90% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	298.41% Upside
MBX MBX Biosciences	3.00	Buy	$37.57	219.76% Upside
RZLT Rezolute	3.14	Buy	$11.83	119.54% Upside

Current Analyst Ratings Breakdown

Latest ACTU, CGEM, MBX, and RZLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/6/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)

Latest ACTU, CGEM, MBX, and RZLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.7951	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.46	0.46
CGEM Cullinan Therapeutics	N/A	11.62	11.62
MBX MBX Biosciences	N/A	N/A	N/A
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
CGEM Cullinan Therapeutics	86.31%
MBX MBX Biosciences	N/A
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
CGEM Cullinan Therapeutics	7.16%
MBX MBX Biosciences	52.19%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
CGEM Cullinan Therapeutics	30	59.01 million	54.79 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
RZLT Rezolute	40	85.52 million	69.79 million	Optionable

ACTU, CGEM, MBX, and RZLT Headlines

Recent News About These Companies

Rezolute Completes Enrollment for Phase 3 sunRIZE Study

July 18 at 6:52 AM | tipranks.com

Rezolute files to sell 1.3M shares of common stock for holders

July 18 at 5:52 AM | msn.com

Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $11.83

July 12, 2025 | americanbankingnews.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of ...

July 10, 2025 | finance.yahoo.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

July 9, 2025 | globenewswire.com

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from Analysts

July 9, 2025 | marketbeat.com

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27, 2025 | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Insider Buys 2,500 Shares of Stock

June 26, 2025 | marketbeat.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25, 2025 | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $20,250.00 in Stock

June 24, 2025 | marketbeat.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Young-Jin Kim Acquires 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 23, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025 | globenewswire.com

Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 21, 2025 | finanznachrichten.de

Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential

May 20, 2025 | finance.yahoo.com

Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment

May 15, 2025 | nasdaq.com

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

FDA grants breakthrough status to Rezolute’s hypoglycemia therapy

May 6, 2025 | investing.com

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025 | globenewswire.com

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Stocks Poised to Benefit From the "Big Beautiful Bill"
By Nathan Reiff | July 7, 2025
View 3 Stocks Poised to Benefit From the "Big Beautiful Bill"
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
5 Robotics Stocks to Buy for the Future of Automation
By Ryan Hasson | July 14, 2025
View 5 Robotics Stocks to Buy for the Future of Automation
Taiwan Semiconductor May Profit from Chinese Manufacturing Issues
By Gabriel Osorio-Mazilli | July 8, 2025
View Taiwan Semiconductor May Profit from Chinese Manufacturing Issues

ACTU, CGEM, MBX, and RZLT Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$5.76 -0.50 (-7.99%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.90 +0.14 (+2.43%)

As of 07/18/2025 05:39 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Cullinan Therapeutics NASDAQ:CGEM

$7.53 -0.24 (-3.09%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.52 0.00 (-0.07%)

As of 07/18/2025 04:20 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

MBX Biosciences NYSE:MBX

$11.75 -0.44 (-3.61%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.73 -0.02 (-0.17%)

As of 07/18/2025 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Rezolute NASDAQ:RZLT

$5.39 -0.15 (-2.71%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.50 +0.11 (+2.04%)

As of 07/18/2025 07:26 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time